Xseer Pharmaceuticals, Inc.
FDA 503B outsourcing facility
Los Angeles, California
Key Takeaways
- FDA-registered 503B outsourcing facility since 2023
- Sterile compounding from bulk substances: Yes
- Not yet inspected by the FDA
About this facility
A 503B outsourcing facility is registered with the FDA under the Drug Quality and Security Act and may compound sterile medications in bulk without patient-specific prescriptions, under cGMP manufacturing standards. How federal compounding status works.
FDA registration and inspection record
- First registered with FDA
- October 21, 2023
- Most recent registration
- December 25, 2025
- Compounds sterile drugs from bulk substances
- Yes
- Last FDA inspection
- Not yet inspected
Xseer Pharmaceuticals, Inc. has registered with the FDA as a 503B outsourcing facility but has not yet been inspected. The FDA inspects registered facilities on a risk-based schedule once drug production and distribution are confirmed.
Compounded peptides and GLP-1s
Xseer Pharmaceuticals, Inc. has not assigned NDCs or filed product reports in the most recent FDA reporting periods. 503B outsourcing facilities are a primary supply route for compounded peptides and GLP-1s during FDA-listed shortages; PeptideGrids grades the evidence for each, including Semaglutide, Tirzepatide, BPC-157, Retatrutide. Browse the GLP-1 and therapeutic peptide databases.
Location
1990 Westwood Blvd, Los Angeles, CA 90025
Satellite and street imagery via Esri. Open larger map.
Contact
FDA-registered contact: Ali Khosrovni, 310-606-0146. Source: the facility's FDA outsourcing registration.
License verification
503B outsourcing facilities are also licensed by the state board of pharmacy. Verify the current license status of Xseer Pharmaceuticals, Inc. with the California State Board of Pharmacy.
503B facilities in California
California has 7 FDA-registered 503B outsourcing facilities in the PeptideGrids directory. See all 503B facilities in California.
Frequently asked questions
Is Xseer Pharmaceuticals, Inc. registered with the FDA?
Yes. Xseer Pharmaceuticals, Inc. is a registered 503B outsourcing facility, first registered with the FDA on October 21, 2023 and most recently registered on December 25, 2025.
Has Xseer Pharmaceuticals, Inc. been inspected by the FDA?
Xseer Pharmaceuticals, Inc. has registered with the FDA but has not yet been inspected as a 503B outsourcing facility.
Has Xseer Pharmaceuticals, Inc. had any FDA drug recalls?
No FDA drug recalls are matched to Xseer Pharmaceuticals, Inc. in the openFDA enforcement database.
What does Xseer Pharmaceuticals, Inc. compound?
Xseer Pharmaceuticals, Inc. has not filed product reports with NDC-assigned drugs in the most recent FDA reporting periods.
Where is Xseer Pharmaceuticals, Inc. located?
Xseer Pharmaceuticals, Inc. is located in Los Angeles, California (1990 Westwood Blvd).
Registration and inspection data verified against the FDA list of registered outsourcing facilities on June 6, 2026.
PeptideGrids is independent and not affiliated with, endorsed by, or sponsored by Xseer Pharmaceuticals, Inc.. Listings, registration, inspection, and recall data are reported from public FDA records for informational purposes only. A recall or inspection finding is not an accusation of current wrongdoing. This is not medical or legal advice. To request a correction, see our corrections policy.